Sorting substances for the purpose of determining their capacity for sebosuppressive activity in topical skin treatment, an in vivo test involves: choosing a substance from ligands of aryl hydrocarbon receptor (AhR)； choosing a mammal expressing cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) gene； treating part of skin of mammal comprising sebaceous glands, with a composition containing substance following a dose/response/response time protocol； examining by immunohistochemical staining expression of CYP1A1 in sebaceous glands of mammal； and selecting substance. Sorting substances for the purpose of determining their capacity for sebosuppressive activity in topical skin treatment, an in vivo test involves: choosing a substance from among the ligands of the aryl hydrocarbon receptor (AhR)； choosing a mammal expressing the cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) gene； treating via topical route part of the skin of the mammal comprising sebaceous glands, with a composition containing the substance following a dose/response/response time protocol； examining by immunohistochemical staining the expression of CYP1A1 in sebaceous glands of the part of the skin of the mammal； and selecting the substance as a function of the sequence of onset of immunohistochemical staining in several different types of cells of the sebaceous glands. Independent claims are included for the following: (1) a composition (C1) for treating and/or preventing skin diseases of a human being, particularly acne, seborrheic dermatitis and rosacea, where the composition is configured to treat and/or prevent hyperseborrhea by means of topical application of the composition on a skin, comprising: an active substance selected from AhR agonist ligands having: an ability to activate the AhR receptor； an ability to modulate a gene regulated by AhR； a short half-life in the human organism of 2-96 hours； a measurable positive effect on a recognized criterion of hyperseborr
